Peroxisome proliferator–activated receptor delta and liver diseases
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in transcriptional regulation and play an important role in many physiological and metabolic processes. Unlike PPAR-alpha and PPAR-gamma, PPAR-delta is ubiquitously expressed, and its activity is key to maintaining pr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2025-02-01
|
| Series: | Hepatology Communications |
| Online Access: | http://journals.lww.com/10.1097/HC9.0000000000000646 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540476943630336 |
|---|---|
| author | Tomoo Yamazaki Edward E. Cable Bernd Schnabl |
| author_facet | Tomoo Yamazaki Edward E. Cable Bernd Schnabl |
| author_sort | Tomoo Yamazaki |
| collection | DOAJ |
| description | Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in transcriptional regulation and play an important role in many physiological and metabolic processes. Unlike PPAR-alpha and PPAR-gamma, PPAR-delta is ubiquitously expressed, and its activity is key to maintaining proper metabolic homeostasis within the liver. PPAR-delta not only regulates physiologic processes of lipid, glucose, and bile acid metabolism but also attenuates pathologic responses to alcohol metabolism, inflammation, fibrosis, and carcinogenesis, and is considered an important therapeutic target in liver diseases. Promising results have been reported in clinical trials for PPAR-delta agonists in liver disease, and the selective agonist seladelpar was recently conditionally approved in the United States as a new treatment option for primary biliary cholangitis. This review provides an overview of PPAR-delta’s function and biology in the liver, examines its kinetics and therapeutic potential across different liver diseases, and discusses the current status of clinical trials involving its agonists. |
| format | Article |
| id | doaj-art-9d60aeeeaf8f41ae8cf50a544ad3f5e6 |
| institution | Kabale University |
| issn | 2471-254X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj-art-9d60aeeeaf8f41ae8cf50a544ad3f5e62025-02-05T02:11:00ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2025-02-019210.1097/HC9.0000000000000646HC90000000000000646Peroxisome proliferator–activated receptor delta and liver diseasesTomoo Yamazaki0Edward E. Cable1Bernd Schnabl2 1 Department of Medicine, University of California San Diego, La Jolla, California, USA 3 CymaBay Therapeutics, Fremont, California, USA 1 Department of Medicine, University of California San Diego, La Jolla, California, USAPeroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in transcriptional regulation and play an important role in many physiological and metabolic processes. Unlike PPAR-alpha and PPAR-gamma, PPAR-delta is ubiquitously expressed, and its activity is key to maintaining proper metabolic homeostasis within the liver. PPAR-delta not only regulates physiologic processes of lipid, glucose, and bile acid metabolism but also attenuates pathologic responses to alcohol metabolism, inflammation, fibrosis, and carcinogenesis, and is considered an important therapeutic target in liver diseases. Promising results have been reported in clinical trials for PPAR-delta agonists in liver disease, and the selective agonist seladelpar was recently conditionally approved in the United States as a new treatment option for primary biliary cholangitis. This review provides an overview of PPAR-delta’s function and biology in the liver, examines its kinetics and therapeutic potential across different liver diseases, and discusses the current status of clinical trials involving its agonists.http://journals.lww.com/10.1097/HC9.0000000000000646 |
| spellingShingle | Tomoo Yamazaki Edward E. Cable Bernd Schnabl Peroxisome proliferator–activated receptor delta and liver diseases Hepatology Communications |
| title | Peroxisome proliferator–activated receptor delta and liver diseases |
| title_full | Peroxisome proliferator–activated receptor delta and liver diseases |
| title_fullStr | Peroxisome proliferator–activated receptor delta and liver diseases |
| title_full_unstemmed | Peroxisome proliferator–activated receptor delta and liver diseases |
| title_short | Peroxisome proliferator–activated receptor delta and liver diseases |
| title_sort | peroxisome proliferator activated receptor delta and liver diseases |
| url | http://journals.lww.com/10.1097/HC9.0000000000000646 |
| work_keys_str_mv | AT tomooyamazaki peroxisomeproliferatoractivatedreceptordeltaandliverdiseases AT edwardecable peroxisomeproliferatoractivatedreceptordeltaandliverdiseases AT berndschnabl peroxisomeproliferatoractivatedreceptordeltaandliverdiseases |